We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bespak | LSE:BPK | London | Ordinary Share | GB0000946276 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 667.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMCSRT
RNS Number : 3961E
Consort Medical PLC
03 November 2015
Consort Medical plc
3 November 2015
Appointment of Group General Counsel and Company Secretary
Consort Medical plc announces that John Ilett has joined the Company as Group General Counsel and Company Secretary with immediate effect.
John has over 20 years of experience in the pharmaceutical/life sciences sector and brings a wealth of experience to the position from previous senior legal roles. These include at LGC Group Limited where he was General Counsel and Company Secretary from 2010 to 2015, and senior legal roles at Biomarin Pharmaceutical, Inc., Cephalon, Inc., Oxford Glycosciences plc and British Biotech plc. John also worked in private practice for several years at Stringer Saul (now Faskens). John is a qualified solicitor.
Enquiries:
Consort Medical Tel: +44 1442 867 Jonathan Glenn - Chief Executive Officer 920 Richard Cotton - Chief Financial Officer FTI Consulting Tel: +44 203 727 Ben Atwell/ Simon Conway 1000
Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.
Our businesses
Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.
Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.
We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). To learn more about our company visit our website at www.consortmedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
COSFSIFEDFISELF
(END) Dow Jones Newswires
November 03, 2015 07:47 ET (12:47 GMT)
1 Year Bespak Chart |
1 Month Bespak Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
